Trial Profile
A Phase 2 Study Using Stereotactic Ablative Radiation Therapy and Ipilimumab in Patients With Oligometastatic Melanoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 19 Dec 2018 Planned End Date changed from 1 Jun 2018 to 31 Dec 2019.
- 19 Dec 2018 Planned primary completion date changed from 1 Jun 2018 to 31 Dec 2019.
- 21 Nov 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.